Today, Genentech provided the following statement regarding reports of particulate matter in vials of Hemlibra.
MyBDC is a new way to ensure the community’s voice is heard.
The National Hemophilia Foundation and the Hemophilia Federation of America continue to follow up on issues arising from Genentech’s recent announcement regarding reports of particulate matter in vials of Hemlibra.
This new approval represents an expansion of the therapy's initial VWD indication, which was granted by the FDA in 2009.
A brief update to the community concerning a recent meeting with the FDA, and additional resources that the FDA provided.
More than 2,500 attendees gathered in Anaheim, CA to gain valuable information and support.
NHF presented Awards of Excellence to medical professionals, chapter leaders, advocates, and volunteers at the Awards Ceremony at the 2019 Bleeding Disorders Conference in Anaheim, CA.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car